Role of Fiber Shaft Length in Tumor Targeting with Ad5/3 Vectors

被引:1
|
作者
Richter, Maximilian [1 ]
Wang, Hongjie [1 ]
Lieber, Andre [1 ]
机构
[1] Univ Washington, Dept Med, Div Med Genet, Seattle, WA 98195 USA
关键词
oncolytic virus; serotype; 3; desmoglein; 2; coagulation factor X; ONCOLYTIC ADENOVIRUS; INTRAVENOUS-INJECTION; GENE-TRANSFER; DESMOGLEIN; IN-VITRO; EXPRESSION; THERAPY; CELLS; TRANSDUCTION; FLEXIBILITY;
D O I
10.3390/genes13112056
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Desmoglein 2 (DSG2) is overexpressed in many epithelial cancers and therefore represents a target receptor for oncolytic viruses, including Ad5/3-based viruses. For most Ad serotypes, the receptor-binding fiber is composed of tail, shaft, and knob domains. Here, we investigated the role of the fiber shaft in Ad5/3 tumor transduction in vitro and in human DSG2-transgenic mice carrying human DSG2(high) tumors. DSG2tg mice express DSG2 in a pattern similar to humans. We constructed Ad5/3L (with the "long" Ad5 shaft) and Ad5/3S (with the "short" Ad3 shaft) expressing GFP or luciferase. In in vitro studies we found that coagulation factor X, which is known to mediate undesired hepatocyte transduction of Ad5, enhances the transduction of Ad5/3(L), but not the transduction of Ad5/3(S). We therefore hypothesized that Ad5/3(S) would target DSG2(high) tumors while sparing the liver after intravenous injection. In vivo imaging studies for luciferase and analysis of luciferase activity in isolated organs, showed that Ad5/3(L) vectors efficiently transduced DSG2(high) tumors and liver but not normal epithelial tissues after intravenous injection. Ad5/3(S) showed minimal liver transduction, however it failed to transduce DSG2(high) tumors. Further modifications of the Ad5/3(S) capsid are required to compensate for the lower infectivity of Ad5/3(S) vectors.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] Development of chimeric Ad5/Ad49 adenovirus vectors that exhibit enhanced tropism for tumour cell lines
    Baker, Alexander
    Davies, James
    Uusi-Kerttula, Hanni
    Ferla, Salvatore
    Brancale, Andrea
    Wilkinson, Gavin
    Chester, John
    Parker, Alan
    HUMAN GENE THERAPY, 2017, 28 (08) : A14 - A14
  • [22] The effect of artificial lipid envelopment of Adenovirus 5 (Ad5) on liver de-targeting and hepatotoxicity
    Yilmazer, Acelya
    Al-Jamal, Wafa' T.
    Van den Bossche, Jeroen
    Kostarelos, Kostas
    BIOMATERIALS, 2013, 34 (04) : 1354 - 1363
  • [23] An adenovirus type 5 (Ad5) amplicon-based packaging cell line for production of high-capacity helper-independent ΔE1-E2-E3-E4 Ad5 vectors
    Catalucci, D
    Sporeno, E
    Cirillo, A
    Ciliberto, G
    Nicosia, A
    Colloca, S
    JOURNAL OF VIROLOGY, 2005, 79 (10) : 6400 - 6409
  • [24] Improved gtioblastoma treatment with Ad5/35 fiber chimeric conditionally replicating adenoviruses
    Hoffmann, Dennis
    Meyer, Bernhard
    Wildner, Oliver
    JOURNAL OF GENE MEDICINE, 2007, 9 (09): : 764 - 778
  • [25] Alternative Serotype Adenovirus Vaccine Vectors Elicit Memory T Cells with Enhanced Anamnestic Capacity Compared to Ad5 Vectors
    Penaloza-MacMaster, Pablo
    Provine, Nicholas M.
    Ra, Joshua
    Borducchi, Erica N.
    McNally, Anna
    Simmons, Nathaniel L.
    Iampietro, Mark J.
    Barouch, Dan H.
    JOURNAL OF VIROLOGY, 2013, 87 (03) : 1373 - 1384
  • [26] Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes
    Zafar, Sadia
    Quixabeira, Dafne Carolina Alves
    Kudling, Tatiana Viktorovna
    Cervera-Carrascon, Victor
    Santos, Joao Manuel
    Gronberg-Vaha-Koskela, Susanna
    Zhao, Fang
    Aronen, Pasi
    Heinio, Camilla
    Havunen, Riikka
    Sorsa, Suvi
    Kanerva, Anna
    Hemminki, Akseli
    CANCER GENE THERAPY, 2021, 28 (05) : 442 - 454
  • [27] Serotype Chimeric and Fiber-Mutated Adenovirus Ad5/19p-HIT for Targeting Renal Cancer and Untargeting the Liver
    Diaconu, Iulia
    Denby, Laura
    Pesonen, Sari
    Cerullo, Vincenzo
    Bauerschmitz, Gerd J.
    Guse, Kilian
    Rajecki, Maria
    Dias, Joao D.
    Taari, Kimmo
    Kanerva, Anna
    Baker, Andrew H.
    Hemminki, Akseli
    HUMAN GENE THERAPY, 2009, 20 (06) : 611 - 620
  • [28] Biodistribution and Inflammatory Profiles of Hepatocyte-Detargeted FX-Binding Ablated Ad5 Vectors
    Alba, Raul
    Bradshaw, Angela C.
    McDonald, Robert A.
    Coughlan, Lynda
    Parker, Alan L.
    Miller, Ashley M.
    van Rooijen, Nico
    Nicklin, Stuart A.
    Baker, Andrew H.
    HUMAN GENE THERAPY, 2010, 21 (04) : 498 - 499
  • [29] Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes
    Sadia Zafar
    Dafne Carolina Alves Quixabeira
    Tatiana Viktorovna Kudling
    Victor Cervera-Carrascon
    Joao Manuel Santos
    Susanna Grönberg-Vähä-Koskela
    Fang Zhao
    Pasi Aronen
    Camilla Heiniö
    Riikka Havunen
    Suvi Sorsa
    Anna Kanerva
    Akseli Hemminki
    Cancer Gene Therapy, 2021, 28 : 442 - 454
  • [30] Enhanced adenovirus infection of melanoma cells by fiber-modification - Incorporation of RGD peptide or Ad5/3 chimerism
    Volk, AL
    Rivera, AA
    Kanerva, A
    Bauerschmitz, G
    Dmitriev, I
    Nettelbeck, DM
    Curiel, DT
    CANCER BIOLOGY & THERAPY, 2003, 2 (05) : 511 - 515